Table 1. PML influences the disease profiles of p53+/R175 mice .
| (A) PML loss influences tumor profiles in p53+/R172H mice (% tumor type) | |||
|---|---|---|---|
| Tumor types | p53+/R172H PML+/+ | p53+/R172H PML+/− | p53+/R172H PML−/− |
| Lymphoma | 52% | 43% | 36% |
| Sarcoma | 43% | 52% | 59% |
| Carcinoma | 4% | 5% | 5% |
| No. tumors | 23 | 21 | 22 |
| No. of mice with tumors | 20 | 17 | 18 |
| (B) PML loss influences disease manifestation p53+/R172H mice (% disease/total no. mice) | |||
|---|---|---|---|
| Tumor types | P53+/R172H PML+/+ | p53+/R172H PML+/− | p53+/R172H PML−/− |
| Lymphoma | 44% | 38% | 44% |
| EMH | 41% | 33% | 0% |
| Sarcoma | 37% | 46% | 72% |
| Carcinoma | 4% | 4% | 6% |
| No. tumors | 23 | 21 | 22 |
| Total no. mice | 27 | 24 | 18 |
| Mean survival | 499d | 504d | 448d |
| (C) Tumor spectrum is influenced by gender and PML loss in p53+/R172H mice (% disease/total no. mice) | |||||
|---|---|---|---|---|---|
| p53+/R172H male mice | |||||
| Tumor types | p53+/R172H PML+/+ | p53+/R172H PML+/− | p53+/R172H PML−/− | ||
| Lymphoma | 50% | 33% | 44% | ||
| EMH | 43% | 33% | 0% | ||
| Osteosarcoma | 14% | 8% | 33% | ||
| Soft tissue sarcoma | 14% | 42% | 44% | ||
| Carcinoma | 0% | 0% | 0% | ||
| No. tumors | 10 | 11 | 11 | ||
| No. mice | 14 | 12 | 9 | ||
| p53+/R172H female mice | |||||
| Tumor types | p53+/R172H PML+/+ | p53+/R172H PML+/− | p53+/R172H PML−/− | ||
| Lymphoma | 38% | 42% | 44% | ||
| EMH | 31% | 33% | 0% | ||
| Osteosarcoma | 38% | 25% | 56% | ||
| Soft tissue sarcoma | 8% | 17% | 11% | ||
| Carcinoma | 8% | 8% | 11% | ||
| No. tumors | 13 | 10 | 11 | ||
| No. mice | 13 | 12 | 9 | ||